Around 4 million babies a year receive non-invasive breathing support worldwide. At A$50–70 per device and around 33 tubes per baby (clinician estimate), that is a global opportunity of almost A$8 billion in hospital spend, with a A$283M serviceable market across Australia, the US, the UK, Canada and India. Beachhead: seven Australian NICUs where the founder has clinical relationships. The design could extend to high-flow, term and paediatric patients over time.

A$500K pre-seed, priced equity, with Brisbane Angels at deal stage. Funds take NeoDuoFlo™ to first-in-human ready: bench validation under design control, a neonatal preclinical study at The University of Queensland, regulatory groundwork (FDA Q-Submission and CE marking pathway), IP and prototyping, with first-in-human planned for 2027.

Raising A$500K pre-seed (priced equity) to make NeoDuoFlo® first-in-human ready. Brisbane Angels are at deal stage, and the round closes in November 2026. The funds take us through the milestones that turn a validated concept into a clinical-stage company: bench validation under design control, a neonatal preclinical study with The University of Queensland, regulatory groundwork towards an FDA Q-Submission and the CE marking pathway, and continued IP protection and prototyping. A 1:3 match has been applied for through the Queensland Female Founders Co-Investment Fund, which would extend every investor dollar further. ESIC eligibility is being confirmed, which may give eligible investors access to early-stage tax incentives.